FR Doc E7-17712
[Federal Register: September 7, 2007 (Volume 72, Number 173)]
[Notices]
[Page 51407]
From the Federal Register Online via GPO Access
[wais.access.gpo.gov]
[DOCID:fr07se07-31]
-----------------------------------------------------------------------
DEPARTMENT OF
COMMERCE
Foreign-Trade Zones
Board
[Docket 44-2007]
Foreign-Trade Zone 7--Mayag[uuml]ez, PR, Application for
Subzone,
Lilly del Caribe, Inc. (Pharmaceutical Manufacturing)
An
application has been submitted to the Foreign-Trade Zones
Board
(the Board) by the Puerto Rico Industrial Development Company
(PRIDCO),
grantee of FTZ 7, requesting special-purpose subzone status for
the
pharmaceutical manufacturing and warehousing facilities of Lilly
del
Caribe, Inc. (Lilly) located in Carolina, Mayag[uuml]ez and
Guayama,
Puerto Rico. The application was submitted pursuant to the
provisions
of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-81u), and
the
regulations of the Board (15 CFR part 400). The application was
filed
on August 27, 2007.
The Lilly facilities consist of 3 sites on 375
acres in Puerto
Rico. Proposed Site 1 (181 acres, buildings totaling 1,303,852 sq.
ft,
of which 433,860 sq. ft. is devoted to manufacturing) is located
at
65th Infantry Road, Km 12.6, in Carolina, Puerto Rico. Proposed
Site 2
(146 acres, buildings totaling 250,499 sq. ft., of which 106, 745
sq.
ft. is devoted to manufacturing) is located at State Road 53, Km.
82,
Jobos exit, in Guayama, Puerto Rico. Proposed Site 3 (48
acres,
buildings totaling 103,816
sq. ft.) is located at No. 3080 Ave Hostos
(Carr 2), in Mayag[uuml]ez, Puerto Rico. The facilities in
Carolina and Guayama are used by Lilly for manufacturing
operations
involving active pharmaceutical ingredients, while the facility
in
Mayag[uuml]ez is used for warehousing, storage and other
manufacturing
support activities. The application indicates that Lilly
employs
approximately 1,490 employees at the sites.
Lilly has requested authority to manufacture two
pharmaceutical
products, Humalog (HTSUS 2937.12) and Duloxetine (HTSUS 2934.99)
for
the U.S. market and export. Duty rates on the finished products
range
from duty-free to 6.5 percent, ad valorem. Foreign components
that
would be used in the manufacturing process (up to 25 percent of
total
content) include prepared binders for foundry molds or cores
(HTSUS
3824.90) and halogenated derivatives of aromatic hydrocarbons
(HTSUS
2903.69), with duty rates of 5.0 and 5.5 percent,
respectively.
The application also requests authority to
include a broad range of
inputs and finished
pharmaceutical products that Lilly may produce
under FTZ procedures in the future. New major activity involving
these
inputs/products would require review by the FTZ Board.
Zone procedures could exempt Lilly from customs
duty payments on
the foreign components used in export production. On domestic
sales,
Lilly could defer duty until the products are entered for
consumption,
and choose the lower duty that applies to the finished product for
the
foreign components used in production. The company would also
realize
certain logistical savings related to zone-to-zone transfers and
direct
delivery procedures, as well as savings on materials that become
scrap/
waste during manufacturing. The application indicates that
FTZ-related
savings would help improve Lilly's international
competitiveness.
Public comment is invited from interested
parties. Submissions
(original and 3 copies) shall be addressed to the Board's
Executive
Secretary at the address below. The closing period for their
receipt is
November 6, 2007. Rebuttal
comments in response to material submitted
during the foregoing period may be submitted during the subsequent
15-
day period (to November 21, 2007).
A copy of the application and accompanying
exhibits will be
available for public inspection at each of the following
locations:
U.S. Department of Commerce Export Assistance
Center, Centro
Internacional de Mercadeo, Tower II, Suite 702, Road 165,
Guaynabo,
Puerto Rico, 00968-8058.
Office of the Executive Secretary, Foreign-Trade
Zones Board, U.S.
Department of Commerce, Room 2111, 1401 Constitution Ave.,
NW.,
Washington, DC 20230.
For further information, contact Christopher
Kemp at
christopher_kemp@ita.doc.gov or (202) 482-0862.
Dated:
August 27, 2007.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E7-17712 Filed 9-6-07; 8:45 am]
BILLING CODE
3510-DS-P